PMID- 25204974
OWN - NLM
STAT- MEDLINE
DCOM- 20150331
LR  - 20220409
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 64
IP  - 2
DP  - 2015 Feb
TI  - Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells.
PG  - 587-92
LID - 10.2337/db14-0656 [doi]
AB  - The retention of endogenous insulin secretion in type 1 diabetes is an attractive 
      clinical goal, which opens possibilities for long-term restoration of glucose 
      metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, 
      a promising interventional strategy for the disease. This prospective clinical 
      study describes the translation of this cellular intervention strategy to 
      patients with recent-onset type 1 diabetes. Twenty adult patients with newly 
      diagnosed type 1 diabetes were enrolled and randomized to MSC treatment or to the 
      control group. Residual beta-cell function was analyzed as C-peptide concentrations 
      in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. 
      In contrast to the patients in the control arm, who showed loss in both C-peptide 
      peak values and C-peptide when calculated as area under the curve during the 1st 
      year, these responses were preserved or even increased in the MSC-treated 
      patients. Importantly, no side effects of MSC treatment were observed. We 
      conclude that autologous MSC treatment in new-onset type 1 diabetes constitutes a 
      safe and promising strategy to intervene in disease progression and preserve 
      beta-cell function.
CI  - (c) 2015 by the American Diabetes Association. Readers may use this article as long 
      as the work is properly cited, the use is educational and not for profit, and the 
      work is not altered.
FAU - Carlsson, Per-Ola
AU  - Carlsson PO
AD  - Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden 
      Department of Medical Sciences, Uppsala University, Uppsala, Sweden 
      per-ola.carlsson@mcb.uu.se.
FAU - Schwarcz, Erik
AU  - Schwarcz E
AD  - Department of Internal Medicine, Orebro University Hospital, Orebro, Sweden.
FAU - Korsgren, Olle
AU  - Korsgren O
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 
      Sweden.
FAU - Le Blanc, Katarina
AU  - Le Blanc K
AD  - Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
SI  - ClinicalTrials.gov/NCT01068951
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140909
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - IM
CIN - Nat Rev Endocrinol. 2014 Dec;10(12):701. PMID: 25265979
MH  - Adult
MH  - Diabetes Mellitus, Type 1/*metabolism
MH  - Female
MH  - Humans
MH  - Insulin-Secreting Cells/*physiology
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*physiology
EDAT- 2014/09/11 06:00
MHDA- 2015/04/01 06:00
CRDT- 2014/09/11 06:00
PHST- 2014/09/11 06:00 [entrez]
PHST- 2014/09/11 06:00 [pubmed]
PHST- 2015/04/01 06:00 [medline]
AID - db14-0656 [pii]
AID - 10.2337/db14-0656 [doi]
PST - ppublish
SO  - Diabetes. 2015 Feb;64(2):587-92. doi: 10.2337/db14-0656. Epub 2014 Sep 9.